Literature DB >> 9351981

Down-regulation of mu-opioid receptor by full but not partial agonists is independent of G protein coupling.

N Yabaluri1, F Medzihradsky.   

Abstract

In C6 glial cells stably expressing rat mu-opioid receptor, opioid agonist activation is negatively coupled to adenylyl cyclase through pertussis toxin-sensitive G proteins. In membranes, [D-Ala2, N-MePhe4,Gly-ol5]enkephalin (DAMGO) increases guanosine-5'-O-(3-[35S]thio)triphosphate (GTP[gamma-35S]) binding by 367% with an EC50 value of 28 nM. Prolonged exposure to agonists induced desensitization of the receptor as estimated by a reduction in the maximal stimulation of GTP[gamma-35S] binding by DAMGO and rightward shifts in the dose-response curves. In cells treated with 10 microM concentrations of etorphine, DAMGO, beta-endorphin, morphine, and butorphanol, DAMGO-stimulated GTP[gamma-35S] binding was 58%, 149%, 205%, 286%, and 325%, respectively. Guanine nucleotide regulation of agonist binding was correspondingly lower in membranes from tolerant cells. Furthermore, chronic opioid treatment increased forskolin-stimulated adenylyl cyclase activity, and potency of DAMGO to inhibit cAMP accumulation was lower in morphine- and DAMGO-tolerant cells (EC50 = 55 and 170 nM versus 18 nM for control). Chronic treatment with agonists reduced [3H]DAMGO binding in membranes with the rank order of etorphine > DAMGO = beta-endorphin > morphine > butorphanol, and the affinity of DAMGO in alkaloid- but not peptide-treated membranes was significantly lower in comparison with control. Pertussis toxin treatment of the cells before agonist treatment did not prevent the down-regulation by full agonists; DAMGO and etorphine exhibited approximately 80% internalization, whereas the ability of partial agonists was greatly impaired. In addition to establishing this cell line as a good model for further studies on the mechanisms of opioid tolerance, these results indicate important differences in the inactivation pathways of receptor triggered by full and partial agonists.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9351981     DOI: 10.1124/mol.52.5.896

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  16 in total

1.  Chronic methadone treatment shows a better cost/benefit ratio than chronic morphine in mice.

Authors:  Johan Enquist; Madeline Ferwerda; Laura Milan-Lobo; Jennifer L Whistler
Journal:  J Pharmacol Exp Ther       Date:  2011-11-07       Impact factor: 4.030

Review 2.  Mu opioid receptor regulation and opiate responsiveness.

Authors:  Kirsten M Raehal; Laura M Bohn
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

3.  Long-term morphine treatment decreases the association of mu-opioid receptor (MOR1) mRNA with polysomes through miRNA23b.

Authors:  Qifang Wu; Lei Zhang; Ping-Yee Law; Li-Na Wei; Horace H Loh
Journal:  Mol Pharmacol       Date:  2009-01-14       Impact factor: 4.436

4.  Postsynaptic signaling via the [mu]-opioid receptor: responses of dorsal horn neurons to exogenous opioids and noxious stimulation.

Authors:  J A Trafton; C Abbadie; K Marek; A I Basbaum
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

5.  Mechanisms of μ-opioid receptor inhibition of NMDA receptor-induced substance P release in the rat spinal cord.

Authors:  Wenling Chen; Helena S Ennes; James A McRoberts; Juan Carlos Marvizón
Journal:  Neuropharmacology       Date:  2017-10-16       Impact factor: 5.250

6.  Endomorphin-1 induced desensitization and down-regulation of the recombinant mu-opioid receptor.

Authors:  C Harrison; D J Rowbotham; D K Grandy; D G Lambert
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

7.  μ-Opioid receptor inhibition of substance P release from primary afferents disappears in neuropathic pain but not inflammatory pain.

Authors:  W Chen; J A McRoberts; J C G Marvizón
Journal:  Neuroscience       Date:  2014-02-26       Impact factor: 3.590

8.  The effect of protein kinase C and G protein-coupled receptor kinase inhibition on tolerance induced by mu-opioid agonists of different efficacy.

Authors:  L C Hull; J Llorente; B H Gabra; F L Smith; E Kelly; C Bailey; G Henderson; W L Dewey
Journal:  J Pharmacol Exp Ther       Date:  2009-12-14       Impact factor: 4.030

9.  Chronic morphine treatment up-regulates mu opioid receptor binding in cells lacking filamin A.

Authors:  Irma Onoprishvili; Eric J Simon
Journal:  Brain Res       Date:  2007-08-16       Impact factor: 3.252

10.  Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.

Authors:  M F Divin; F A Bradbury; F I Carroll; J R Traynor
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.